Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial
An uncomplicated, widely available, prophylactic regimen (COCOON DM) reduced the incidence of DAEIs with amivantamab-lazertinib and the impact of symptoms on QoL.
Authors
- Janellen Smith
- Mark Wildgust
- Farastuk Bozorgmehr (ORCID: https://orcid.org/0000-0001-8058-8884)
- Jorge Simões (ORCID: https://orcid.org/0000-0003-3397-2319)
- Baogang Liu
- Cheng‐Ta Yang (ORCID: https://orcid.org/0000-0003-1846-1027)
- Tonatiuh Romero
- Alexander I. Spira (ORCID: https://orcid.org/0000-0003-1303-0447)
- J. Cundom
- Jin‐Yuan Shih (ORCID: https://orcid.org/0000-0002-2854-5067)
- Glaucio Bertollo
- Danny Nguyen (ORCID: https://orcid.org/0000-0002-2479-2271)
- Julia Schuchard (ORCID: https://orcid.org/0000-0002-8613-8961)
- Mehregan Nematian‐Samani
- Pascale Tomasini (ORCID: https://orcid.org/0000-0002-6474-5912)
- Nuri Karadurmuş (ORCID: https://orcid.org/0000-0003-3291-8062)
- İrfan Çiçin (ORCID: https://orcid.org/0000-0002-7584-3868)
- Seán Murphy (ORCID: https://orcid.org/0000-0002-6582-4065)
- Joshua Bauml (ORCID: https://orcid.org/0000-0003-4193-841X)
- Parthiv J. Mahadevia
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Jill Feldman
- Jorge J. Nieva (ORCID: https://orcid.org/0000-0003-1605-4719)
- Juinn Huar Kam (ORCID: https://orcid.org/0000-0002-2478-9689)
- Maxwell Benjamin Sauder (ORCID: https://orcid.org/0000-0002-5605-3844)
- Shubin Sheng (ORCID: https://orcid.org/0000-0002-7048-1108)
- Milena Perez Mak (ORCID: https://orcid.org/0000-0001-5876-6533)
- Yichuan Xia
- Nicolas Girard (ORCID: https://orcid.org/0000-0002-7636-6688)
- Panwen Tian (ORCID: https://orcid.org/0000-0002-6313-3228)
- Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
- Ana Laura Ortega Granados (ORCID: https://orcid.org/0000-0002-5727-3371)
- Weimin Li (ORCID: https://orcid.org/0000-0003-3664-7802)
- Bruce G. Anderson
- Pei Jye Voon
- Jiunn-Liang Tan
Institutions
- University of Southern California (US)
- Hebron University (PS)
- Universitat Autònoma de Barcelona (ES)
- City Of Hope National Medical Center (US)
- Johnson & Johnson (United States) (US)
- Harbin Medical University (CN)
- Yonsei University (KR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- University of California, Irvine (US)
- Aix-Marseille Université (FR)
- Heidelberg University (DE)
- Sichuan University (CN)
- Université Paris-Saclay (FR)
- Santa Casa Hospital (BR)
- Sarawak General Hospital (MY)
- University Hospital Heidelberg (DE)
- Princess Margaret Cancer Centre (CA)
- University of Malaya (MY)
- Walgreens Boots Alliance (United States) (US)
- Instituto do Câncer do Estado de São Paulo (BR)
- West China Hospital of Sichuan University (CN)
- Gülhane Askerî Tıp Akademisi (TR)
- Instituto Argentino de Diagnóstico y Tratamiento (AR)
- Vall d'Hebron Institut de Recerca (ES)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória (BR)
- Linkou Chang Gung Memorial Hospital (TW)
- USC Norris Comprehensive Cancer Center (US)
- Complejo Hospitalario de Jaén (ES)
- Istinye University (TR)
- Virginia Cancer Specialists (US)
- Vall d'Hebron Hospital Universitari (ES)
- National Taiwan University Hospital (TW)
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- Yonsei University Health System (KR)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2025-09-09
- DOI
- https://doi.org/10.1016/j.jtho.2025.07.117
- Citations
- 15
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 22.78
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Merck KGaA
- Mirati Therapeutics
- BeiGene
- Revolution Medicines
- G1 Therapeutics
- Astellas Pharma
- Ono Pharmaceutical
- Orient Europharma
- Grifols
- LEO Pharma
- Genentech
- University of California, Irvine
- Chugai Pharmaceutical
- Daiichi Sankyo Europe
- Cilag